Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.58 |
| ▸ | MAPT | P10636 | 8/20 | 0.58 |
| ▸ | HTT | P42858 | 7/20 | 0.58 |
| ▸ | MEN1 | O00255 | 7/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 10/20 | 0.56 |
| ▸ | GAA | P10253 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | GBA1 | P04062 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | TEX264 | Q9Y6I9 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23345485 | 0.90 | KMT2A (0.67) | KMT2AMAPTHTTMEN1NPSR1 | |
| SCHEMBL22737807 | 0.82 | MAPT (0.68) | KMT2AMAPTHTTMEN1NPSR1 | |
| SCHEMBL22737374 | 0.82 | MAPT (0.62) | KMT2AMAPTHTTMEN1NPSR1 | |
| SCHEMBL13576487 | 0.81 | LMNA (0.81) | KMT2AMAPTHTTMEN1NPSR1 | |
| SCHEMBL22737384 | 0.81 | MAPT (0.70) | KMT2AMAPTHTTMEN1NPSR1 | |
| SCHEMBL22892510 | 0.81 | MAPT (0.59) | KMT2AMAPTHTTMEN1NPSR1 | |
| SCHEMBL23345459 | 0.80 | KMT2A (0.72) | KMT2AMAPTHTTMEN1NPSR1 | |
| SCHEMBL23345481 | 0.79 | KMT2A (0.70) | KMT2AMAPTHTTMEN1NPSR1 | |
| SCHEMBL23345488 | 0.77 | MAPT (0.86) | KMT2AMAPTHTTMEN1NPSR1 | |
| SCHEMBL8909541 | 0.77 | KMT2A (0.57) | KMT2AMAPTHTTMEN1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200375996-A1 | METHOD OF TREATING NEURODEGENERATIVE DISORDERS BY RESCUING ALPHA-SYNUCLEIN TOXICITY | D.E. SHAW RESEARCH, LLC (US) | 2020-12-03 | — | — | US | disclosed |
| WO-2017106367-A1 | METHOD OF TREATING NEURODEGENERATIVE DISORDERS BY RESCUING ALPHA-SYNUCLEIN TOXICITY | D.E. SHAW RESEARCH, LLC (US) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200375996-A1 | METHOD OF TREATING NEURODEGENERATIVE DISORDERS BY RESCUING ALPHA-SYNUCLEIN TOXICITY | SNCA, PARK7, NEDD4 | KMT2A 2524/4885MAPT 48/4885HTT 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.